Astrana Health, Inc.
ASTHHealthcareNASDAQMedical Care Facilities
Scan Results
Daily timeframeAstrana Health, Inc., a healthcare management company, provides medical care services in the United States. At a $1.86B market cap, Astrana Health, Inc. ranks as a small-cap company within healthcare. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Market Cap
$1.86B
Beta
1.03
P/E (TTM)
45.12
P/E (Fwd)
10.30
EPS (TTM)
$0.83
EPS (Fwd)
$3.64
ROE
6.9%
ROA
3.8%
Cash
$400.8M
Total Debt
$979.4M
Free CF
$231.2M
52W Change
12.5%
Annual Financials
Cash vs Debt
Where ASTH stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ASTH finished 0.57% above its 150-day moving average ($36.69) and 10.48% above its 200-day moving average ($33.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ASTH overbought or oversold?
At the October 20, 2026 close, ASTH's RSI(14) was 58.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Astrana Health, Inc. carries $979.4M in total debt against $400.8M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $231.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 6.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.14B (2022) to $3.18B (2025), reflecting a 178% increase over the period.
As with any equity investment, ASTH carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ASTH.